Regeneron Pharmaceuticals (REGN) Rating Increased to Buy at Guggenheim

Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research report issued on Friday, January 4th, MarketBeat Ratings reports. The brokerage presently has a $461.00 target price on the biopharmaceutical company’s stock. Guggenheim’s price target would suggest a potential upside of 12.82% from the company’s previous close.

REGN has been the subject of a number of other reports. Leerink Swann upped their target price on shares of Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a report on Monday, October 1st. ValuEngine raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, September 6th. Goldman Sachs Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “conviction-buy” rating in a report on Thursday, December 13th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Finally, Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $404.11.

NASDAQ REGN traded up $0.57 during trading hours on Friday, hitting $408.63. The company had a trading volume of 755,441 shares, compared to its average volume of 850,080. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30. Regeneron Pharmaceuticals has a 1-year low of $281.89 and a 1-year high of $416.49. The company has a market capitalization of $43.24 billion, a PE ratio of 30.47, a P/E/G ratio of 1.72 and a beta of 1.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the firm posted $3.99 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals will post 18.88 earnings per share for the current year.

In related news, Director Joseph L. Goldstein sold 1,791 shares of the firm’s stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total transaction of $734,310.00. Following the sale, the director now owns 14,114 shares in the company, valued at $5,786,740. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Christopher R. Fenimore sold 1,848 shares of the firm’s stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $358.97, for a total transaction of $663,376.56. Following the sale, the vice president now owns 9,871 shares in the company, valued at approximately $3,543,392.87. The disclosure for this sale can be found here. Insiders sold 3,645 shares of company stock worth $1,399,980 over the last quarter. Company insiders own 12.42% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rehmann Capital Advisory Group raised its stake in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 68 shares during the period. Signaturefd LLC raised its stake in shares of Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 198 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $159,000. Columbia Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $196,000. Finally, Valeo Financial Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 943.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 500 shares during the period. Hedge funds and other institutional investors own 67.20% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Stock Selection – What is cash flow?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply